Aktienanalyse zu Tandem Diabetes Care Inc (TNDM)TNDMTandem Diabetes Care Inc

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tandem Diabetes Care Inc (TNDM) is a good buy right now due to its current price of $21.43, which is below the analyst price target of $40 set by Canaccord. The company has shown a strong revenue growth of 5.8% year-on-year in Q2 2026, with a total revenue of $254.6 million, exceeding analyst expectations. However, the main risk is its high forward P/E ratio of 1111.11, indicating potential overvaluation concerns.

7 analysts cover TNDM: 1 rate it Buy, 5 Hold and 1 Sell. The average price target is 26.33.